Eris Lifesciences Limited

NSE ERIS.NS

Eris Lifesciences Limited Return on Capital Employed (ROCE) for the year ending March 31, 2024: 11.43%

Eris Lifesciences Limited Return on Capital Employed (ROCE) is 11.43% for the year ending March 31, 2024, a -14.53% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Eris Lifesciences Limited Return on Capital Employed (ROCE) for the year ending March 31, 2023 was 13.37%, a -37.94% change year over year.
Eris Lifesciences Limited Return on Capital Employed (ROCE) for the year ending March 31, 2022 was 21.54%, a -9.39% change year over year.
Eris Lifesciences Limited Return on Capital Employed (ROCE) for the year ending March 31, 2021 was 23.77%, a -1.14% change year over year.
Eris Lifesciences Limited Return on Capital Employed (ROCE) for the year ending March 31, 2020 was 24.04%, a -11.84% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NSE: ERIS.NS

Eris Lifesciences Limited

CEO	Mr. Amit Indubhushan Bakshi
IPO Date	June 30, 2017
Location	India
Headquarters	Shivarth Ambit
Employees	3,620
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Key trends

Past 5 years